Nuvectis Pharma, Inc. NVCT
21.08 USD +0.06 (+0.29%)
At closeNov 10, 2026, 4:01 PM EST
21.08 0.00 0.00%
After hours · Nov 10, 4:01 PM ET
20.23 Day range 21.30
5.77 52-week range 29.28
- YTD
- +179.21%
- 1 year
- +247.28%
Financial health
Altman Z-Score
27.44 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C-1 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 2
Valuation
P/E -5.7×
FY 2020 5y median -5.0× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 8.9×
FY 2020 5y median 8.9× FY 2025
P/FCF -10.3×
FY 2020 5y median -7.6× FY 2025
EV/EBITDA -5.0×
FY 2020 5y median -3.9× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -9.7%
FY 2020 5y median -13.2% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -143.6%
FY 2020 5y median -143.6% FY 2025
ROIC -149.8%
FY 2020 5y median -187.7% FY 2025
ROA -83.4%
FY 2020 5y median -102.1% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -38.9%
FY 2020 FY 2025
EPS (diluted) -18.9%
FY 2020 FY 2025
Free Cash Flow -30.7%
FY 2020 FY 2025
Financial Health
Current Ratio 2.4×
FY 2020 5y median 2.4× FY 2025
Quick Ratio 2.4×
FY 2020 5y median 2.4× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 1.2×
FY 2020 5y median 1.0× FY 2025
Interest Coverage 0.0×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31